ReviewNanomaterials (Basel, Switzerland)2023
Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT/MRI and PET/MRI.
Review in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Magnetically responsive electrospun fibers as programmable bioactive scaffolds: From formulation design to magnetically triggered therapy and regeneration.Bioactive materials · 2027Review
- Nanotechnology-Enabled Targeted Protein Degradation: Strategies, Opportunities, and Challenges.Small methods · 2026Review
- Theranostic Smart Bionanosensors for Solid Tumors: Advances, Challenges, and Future Directions.Applied biochemistry and biotechnology · 2026Review
- Advances in Nuclear Medicine Diagnostics: The Promise of Radiolabeled Dendrimers.Molecules (Basel, Switzerland) · 2026Review
- Engineering intrinsically radiolabeled nanoparticles for imaging and therapy: a decade of design strategies and insights.RSC advances · 2026Review
- Multifunctional Nano-Contrast Agent Carriers: From Traditional Platforms to Next-Generation Theranostic Applications in Molecular Imaging.Biomedicines · 2026Review
- Radiolabelled ZnO, Iron Oxide-Based, and Gold Nanoparticles for Cancer Therapy: Synthesis, Surface Engineering, and Radiolabelling Strategies.International journal of molecular sciences · 2026Review
- Recent advances in the biosensing platforms for sepsis diagnosis.RSC advances · 2026Review
- Nanomaterials and exercise interventions: A synergistic approach for atherosclerosis therapy (Review).International journal of molecular medicine · 2026Review
- The Development and Challenges of PET/MRI Dual-Modality Imaging Probes-An Update.Journal of magnetic resonance imaging : JMRI · 2025Review
- Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy-Implications for Radiopharmaceutical Repurposing (Beyond Oncology).Pharmaceutics · 2025Review
- The Influence of Light Rare-Earth Substitution on Electronic and Magnetic Properties of CoFeNanomaterials (Basel, Switzerland) · 2025Article
- Molecular Imaging: Unveiling Metabolic Abnormalities in Pancreatic Cancer.International journal of molecular sciences · 2025Review
- Multipole Expansion of the Scalar Potential on the Basis of Spherical Harmonics: Bridging the Gap Between the Inside and Outside Spaces via Solution of the Poisson Equation.Materials (Basel, Switzerland) · 2025Article
- Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Unveiling Nanoparticles: Recent Approaches in Studying the Internalization Pattern of Iron Oxide Nanoparticles in Mono- and Multicellular Biological Structures.Journal of functional biomaterials · 2024Review
- Advances and prospects of precision nanomedicine in personalized tumor theranostics.Frontiers in cell and developmental biology · 2024Review
- The Current Status and Future Directions on Nanoparticles for Tumor Molecular Imaging.International journal of nanomedicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last decades, the utilization of imaging modalities such as single photon emission computed tomography (SPECT), positron emission tomography (PET), and magnetic resonance imaging (MRI) in every day clinical practice has enabled clinicians to diagnose diseases accurately at early stages. Radiolabeled iron oxide nanoparticles (RIONs) combine their intrinsic magnetic behavior with the extrinsic character of the radionuclide additive, so that they constitute a platform of multifaceted physical properties. Thus, at a practical level, RIONs serve as the physical parent of the so-called dual-modality contrast agents (DMCAs) utilized in SPECT/MRI and PET/MRI applications due to their ability to combine, at real time, the high sensitivity of SPECT or PET together with the high spatial resolution of MRI. This review focuses on the synthesis and in vivo investigation of both biodistribution and imaging efficacy of RIONs as potential SPECT/MRI or PET/MRI DMCAs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.